Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anxo Pharmaceutical CoROCO:6677 +0.88%66 EV-to-FCF is 240.41 as of Jul. 16, 2026, which is 503% above its 10-year median of 39.84. GuruFocus rates ROCO:6677 with a GF Score™ of 66/100 and a GF Value™ of NT$30.26 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 564 Drug Manufacturers companies, Anxo Pharmaceutical Co ranks worse than 93.62% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Anxo Pharmaceutical Co's Enterprise Value is NT$1,426.8 Mil.
Anxo Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$5.9 Mil. Therefore, Anxo Pharmaceutical Co's EV-to-FCF for today is 240.41.
The historical rank and industry rank for Anxo Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
ROCO:6677'
s EV-to-FCF Range Over the Past 10 Years
Min: -110.57 Med: 39.84 Max: 281.57
Current: 242.77
During the past 13 years, the highest EV-to-FCF of Anxo Pharmaceutical Co was 281.57. The lowest was -110.57. And the median was 39.84.
ROCO:6677's EV-to-FCF is ranked worse than 93.62% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.895
vs ROCO:6677: 242.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anxo Pharmaceutical Co (ROCO:6677) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anxo Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Anxo Pharmaceutical Co's share price for today is NT$17.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anxo Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.610.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anxo Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Anxo Pharmaceutical Co's EV-to-FCF falls into.
Anxo Pharmaceutical Co's current Enterprise Value is NT$1,426.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anxo Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$5.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anxo Pharmaceutical Co (ROCO:6677) has a EV-to-FCF of 240.41 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anxo Pharmaceutical Co and its competitors. This is 503% above median its historical median of 39.84. According to the industry distribution chart, Anxo Pharmaceutical Co ranks #528 out of 564 companies in the Drug Manufacturers industry, placing it in the top 93.6%.
Is Anxo Pharmaceutical Co's EV-to-FCF too high?
Anxo Pharmaceutical Co's current EV-to-FCF of 240.41 is 503% above median its 10-year median of 39.84. The Drug Manufacturers industry median EV-to-FCF is 20.90. Anxo Pharmaceutical Co's value of 240.41 is 1050.6% above this industry median. Based on the distribution chart, Anxo Pharmaceutical Co ranks #528 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Anxo Pharmaceutical Co has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Anxo Pharmaceutical Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anxo Pharmaceutical Co ranks #528 out of 564 companies for EV-to-FCF. This places Anxo Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 20.90. Anxo Pharmaceutical Co's value of 240.41 is 1050.6% above this benchmark. While the company's 10-year median is 39.84 vs. the industry median of 20.90, Anxo Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.90, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anxo Pharmaceutical Co's current EV-to-FCF of 240.41 is 1050.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anxo Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anxo Pharmaceutical Co's current EV-to-FCF is 240.41, which is 503% above median its own 10-year median of 39.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anxo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Anxo Pharmaceutical Co (ROCO:6677) is currently considered Possible Value Trap. The stock's GF Value™ is NT$30.26, compared to a current price of NT$17.20 — trading 43.2% below its estimated fair value. The current EV-to-FCF is 240.41, which is 503% above median its 10-year median of 39.84 and 1050.6% above the Drug Manufacturers industry median of 20.90. Anxo Pharmaceutical Co's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Anxo Pharmaceutical Co (ROCO:6677), the current EV-to-FCF is 240.41 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anxo Pharmaceutical Co (ROCO:6677) Overvalued in 2026?
Based on GuruFocus' analysis, Anxo Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$17.20 is trading 43.2% below its estimated GF Value™ of NT$30.26.
GuruFocus considers Anxo Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for ROCO:6677:
EV-to-FCF: 240.41 (503% above median its 10-year median of 39.84)
GF Value™: NT$30.26 vs. price of NT$17.20 (43.2% below fair value)
Industry Position: 1050.6% above the Drug Manufacturers median (#528 of 564)
No single metric tells the full story. See the ROCO:6677 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.
66GF Score
Get the complete analysis for ROCO:6677
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6677 has been successfully added to your 
